Tune into this episode of PwC's Next in Health to hear Health Research Institute (HRI) leader, Benjamin Isgur, and HRI Regulatory Center leader, Trine Tsouderos in discussion with HRI's Erin McCallister on what pharma might expect from federal agencies, including:

• Food and Drug Administration (FDA)'s potential to broaden / standardized policies implemented in response to the pandemic (i.e., clinical trial diversity, supply chain visibility)
• How politics has impacted FDA productivity
• Centers for Medicare & Medicaid Services (CMS)' approach to control drug spending
• Health and Human Services' role in 340B changes